Intravenous tocilizumab has been demonstrated to be an effective disease modifying agent in the treatment of moderate to severe active thyroid eye disease. The authors describe 2 patients treated with tocilizumab using home subcutaneous administration over an accelerated, biweekly course. Both patients exhibited improvement in thyroid eye disease clinical activity and proptosis.
Subcutaneous tocilizumab demonstrates improvement in clinical disease activity in the setting of moderate thyroid eye disease.
Department of Ophthalmology, University of California, San Francisco, San Francisco, California, U.S.A.
Accepted for publication January 28, 2019.
The authors have no financial or conflicts of interest to disclose.
Address correspondence and reprint requests to M. Reza Vagefi, M.D., Division of Oculofacial Plastic, Reconstructive and Orbital Surgery, Department of Ophthalmology University of California, San Francisco, 10 Koret Way, Rm K327, San Francisco, CA 94143. E-mail: email@example.com